16.15
price up icon0.06%   0.010
after-market 시간 외 거래: 16.15
loading
전일 마감가:
$16.14
열려 있는:
$16.13
하루 거래량:
66,633
Relative Volume:
75.54
시가총액:
$19.42M
수익:
$6.67M
순이익/손실:
$-47.55M
주가수익비율:
-10.77
EPS:
-1.5
순현금흐름:
$-17.44M
1주 성능:
+7.20%
1개월 성능:
+3,059%
6개월 성능:
+3,059%
1년 성능:
+3,059%
1일 변동 폭
Value
$16.06
$16.73
1주일 범위
Value
$15.49
$21.40
52주 변동 폭
Value
$11.06
$21.40

Crescent Biopharma Inc Stock (CBIO) Company Profile

Name
명칭
Crescent Biopharma Inc
Name
전화
-
Name
주소
-
Name
직원
0
Name
트위터
@catalystbio
Name
다음 수익 날짜
2023-11-13
Name
최신 SEC 제출 서류
Name
CBIO's Discussions on Twitter

CBIO을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
CBIO
Crescent Biopharma Inc
16.15 19.42M 6.67M -47.55M -17.44M -1.50
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.16 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
534.91 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.06 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.47 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.16 28.51B 3.81B -644.79M -669.77M -6.24

Crescent Biopharma Inc Stock (CBIO) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-03-21 개시 Cantor Fitzgerald Overweight
2025-03-11 개시 Noble Capital Markets Outperform
2024-07-26 다운그레이드 TD Cowen Buy → Hold
2023-12-22 개시 CapitalOne Overweight
2021-11-12 업그레이드 Jefferies Hold → Buy
2021-04-29 재개 Stephens Overweight
2021-02-10 개시 Piper Sandler Overweight
2020-05-21 개시 Raymond James Outperform
2019-11-14 개시 ROTH Capital Buy
2019-08-05 다운그레이드 Jefferies Buy → Hold
2019-08-05 다운그레이드 Piper Jaffray Overweight → Neutral
2019-08-05 다운그레이드 SunTrust Buy → Hold
2019-04-12 개시 Piper Jaffray Overweight
2019-01-04 개시 Oppenheimer Outperform
2018-12-18 개시 H.C. Wainwright Buy
2018-02-12 재확인 B. Riley FBR, Inc. Buy
2018-02-09 재확인 Chardan Capital Markets Buy
2017-12-08 개시 B. Riley FBR, Inc. Buy
2017-06-12 개시 Chardan Capital Markets Buy
2017-06-06 개시 Ladenburg Thalmann Buy
2016-07-26 개시 SunTrust Buy
2016-06-30 개시 Rodman & Renshaw Buy
2015-03-17 재확인 Stifel Buy
모두보기

Crescent Biopharma Inc 주식(CBIO)의 최신 뉴스

pulisher
Jun 18, 2025

Why Beyond Air Shares Are Trading Lower By Over 23%; Here Are 20 Stocks Moving Premarket - Benzinga

Jun 18, 2025
pulisher
Jun 17, 2025

Why Avidity Biosciences Shares Are Under the Spotlight - TipRanks

Jun 17, 2025
pulisher
Jun 16, 2025

Massive $200M Biotech Deal: Crescent Biopharma Secures Funding for Cancer Breakthrough Pipeline - Stock Titan

Jun 16, 2025
pulisher
Jun 12, 2025

Crisis as catalyst: From Chernobyl evacuation to biotech innovation - BioXconomy

Jun 12, 2025
pulisher
Jun 10, 2025

Gyre Therapeutics announces first doing in Phase 1 trial of F230 - TipRanks

Jun 10, 2025
pulisher
Jun 07, 2025

How To Trade (GYRE) - news.stocktradersdaily.com

Jun 07, 2025
pulisher
Jun 05, 2025

Is Costco's BNPL Push a Catalyst for Big-Ticket E-Commerce? - The Globe and Mail

Jun 05, 2025
pulisher
May 31, 2025

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World

May 31, 2025
pulisher
May 29, 2025

Hemophilia with Inhibitor Market Statistics Expected - openPR.com

May 29, 2025
pulisher
May 29, 2025

A.I. Drone Operations Flourishing as Global Quantum Computing Market Expected to Reach $5.3 Billion By 2029 - The Globe and Mail

May 29, 2025
pulisher
May 29, 2025

Forge Resources Announces Closing of Further Interest to 80% in Fully Permitted Coal Project, Colombia - The Globe and Mail

May 29, 2025
pulisher
May 29, 2025

Quantum Computing Technology Evolving as Larger Scale of Applications & Uses Skyrockets - The Globe and Mail

May 29, 2025
pulisher
May 29, 2025

AI Analyst Flags Key Risks and Upside for Nvidia Ahead of Earnings - The Globe and Mail

May 29, 2025
pulisher
May 29, 2025

Prediction: SoundHound AI Stock Will Beat the Market. Here's Why. - The Globe and Mail

May 29, 2025
pulisher
May 29, 2025

Zacks Investment Ideas feature highlights: CyberArk, Lam Research and monday.com - The Globe and Mail

May 29, 2025
pulisher
May 27, 2025

(GYRE) Long Term Investment Analysis - news.stocktradersdaily.com

May 27, 2025
pulisher
May 23, 2025

SBAC Stock Rises 12% Year to Date: Will the Trend Continue? - The Globe and Mail

May 23, 2025
pulisher
May 23, 2025

GYRE Trading Resumes After Temporary Halt | GYRE Stock News - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Trading Halted for Catalyst Biosciences (GYRE) Due to Volatility - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Trading Halted for Catalyst Biosciences (GYRE) Due to Volatility | GYRE Stock News - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Factor Investing in Focus: What ETFs Say About Market Direction - The Globe and Mail

May 23, 2025
pulisher
May 23, 2025

Is Navitas Semiconductor Stock a buy After Nvidia Enters the Room? - The Globe and Mail

May 23, 2025
pulisher
May 22, 2025

Where Will Rigetti Computing Be in 3 Years? - The Globe and Mail

May 22, 2025
pulisher
May 21, 2025

Here's How I'd Invest $10,000 Today - The Globe and Mail

May 21, 2025
pulisher
May 17, 2025

How the (GYRE) price action is used to our Advantage - news.stocktradersdaily.com

May 17, 2025
pulisher
May 16, 2025

Barclays Reaffirms Their Hold Rating on Floor & Decor Holdings (FND) - The Globe and Mail

May 16, 2025
pulisher
May 15, 2025

Why JD.com Stock Slumped on Thursday - The Globe and Mail

May 15, 2025
pulisher
May 07, 2025

Will Crimson Data Add Shine To Catalyst Biosciences? - RTTNews

May 07, 2025
pulisher
May 07, 2025

Where are the Opportunities in (GYRE) - news.stocktradersdaily.com

May 07, 2025
pulisher
Apr 28, 2025

IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events – Company Announcement - Financial Times

Apr 28, 2025
pulisher
Apr 24, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 24, 2025
pulisher
Apr 22, 2025

Corteva Invests in Desert Bacteria Startup That Boosted Crop Yields 15% Across 800,000 Acres - Stock Titan

Apr 22, 2025
pulisher
Apr 22, 2025

Puna Bio receives investment from Corteva Catalyst - Yahoo Finance

Apr 22, 2025
pulisher
Apr 19, 2025

Carnival Is Down 27% in 2025. Is This a Once-in-a-Lifetime Buying Opportunity Before the Stock Goes Parabolic? - The Globe and Mail

Apr 19, 2025
pulisher
Apr 16, 2025

Bright Minds Biosciences: A Buy With A Major Catalyst In Q2 2025 (NASDAQ:DRUG) - Seeking Alpha

Apr 16, 2025
pulisher
Apr 16, 2025

AbCellera: Attractively Priced But A Catalyst Is Needed - Seeking Alpha

Apr 16, 2025
pulisher
Apr 15, 2025

Spotting Winners: Teleflex (NYSE:TFX) And Surgical Equipment & ConsumablesSpecialty Stocks In Q4 - The Globe and Mail

Apr 15, 2025
pulisher
Apr 14, 2025

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Purchased by Geode Capital Management LLC - Defense World

Apr 14, 2025
pulisher
Apr 14, 2025

Wellington Management Group LLP Sells 8,034 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World

Apr 14, 2025
pulisher
Apr 11, 2025

Biotech Stocks Are Tumbling — But The Top 5 Are Standouts - Investor's Business Daily

Apr 11, 2025
pulisher
Apr 05, 2025

(GYRE) Proactive Strategies - news.stocktradersdaily.com

Apr 05, 2025
pulisher
Apr 05, 2025

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Bought by Sei Investments Co. - Defense World

Apr 05, 2025
pulisher
Apr 02, 2025

Arcus Biosciences: A High-Risk Speculation With Multiple Large, Near-Term Catalysts - Seeking Alpha

Apr 02, 2025
pulisher
Mar 31, 2025

Gyre Therapeutics announces NMPA approval for trial on pirfenidone - TipRanks

Mar 31, 2025
pulisher
Mar 28, 2025

Business - isStories

Mar 28, 2025
pulisher
Mar 27, 2025

Gyre Therapeutics announces publication of protocol for Phase 3 trial on F351 - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Catalyst Pharma Battles To All-Time High After Huge Patent Lawsuit Win - Investor's Business Daily

Mar 27, 2025
pulisher
Mar 21, 2025

GyreIntriguing Upcoming Data Catalyst, But I'm Still On Sidelines (NASDAQ:GYRE) - Seeking Alpha

Mar 21, 2025
pulisher
Mar 18, 2025

3 Reasons to Avoid LUMN and 1 Stock to Buy Instead - The Globe and Mail

Mar 18, 2025
pulisher
Mar 17, 2025

Hemophilia B Pipeline 2024: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | Novo Nordisk, Sanofi, Pfizer, Belief BioMed, Centessa Pharma - Barchart

Mar 17, 2025
pulisher
Mar 17, 2025

Avidity Biosciences Shares Tumble Despite Trial Success - TipRanks

Mar 17, 2025

Crescent Biopharma Inc (CBIO) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Crescent Biopharma Inc 주식 (CBIO) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Invus Public Equities, L.P.
10% Owner
Aug 07 '24
Sale
0.18
61,488
11,197
6,578,438
Invus Public Equities, L.P.
10% Owner
Aug 05 '24
Sale
0.19
164,523
30,996
6,695,658
Invus Public Equities, L.P.
10% Owner
Aug 06 '24
Sale
0.18
55,732
10,188
6,639,926
Invus Public Equities, L.P.
10% Owner
Aug 02 '24
Sale
0.20
286,200
57,354
6,860,181
Invus Public Equities, L.P.
10% Owner
Aug 01 '24
Sale
0.22
63,564
13,743
7,146,381
Invus Public Equities, L.P.
10% Owner
Jul 30 '24
Sale
0.22
756,835
167,185
7,209,945
Invus Public Equities, L.P.
10% Owner
Jul 29 '24
Sale
0.24
363,949
85,637
7,966,780
Invus Public Equities, L.P.
10% Owner
Jul 26 '24
Sale
0.24
258,335
62,440
8,330,729
$20.74
price up icon 0.39%
$35.88
price down icon 0.42%
$21.20
price down icon 0.38%
$97.62
price down icon 3.00%
$107.51
price up icon 0.98%
biotechnology ONC
$245.16
price up icon 1.28%
자본화:     |  볼륨(24시간):